July 21, 2026
The attorneys general of Texas and Louisiana pushed back on Tuesday against a bid from Novo Nordisk and Eli Lilly to duck a specialty pharmacy's antitrust case accusing the companies of blocking competition for GLP-1 medications.
April 29, 2026
Pharmaceutical giant Novo Nordisk told a Texas federal judge that it does not control the GLP-1 market and has not attempted to crush its competition in a bid to dismiss an antitrust suit it is facing.
January 20, 2026
Law360 Healthcare Authority looks at a challenge by the American Academy of Pediatrics to recent changes in federal childhood vaccine recommendations, a patent case set for U.S. Supreme Court review concerning "skinny labels" on generic drugs and other significant litigation developments impacting the healthcare industry this week.
January 14, 2026
Eli Lilly & Co. and Novo Nordisk are using their dominant positions in the market for weight loss and diabetes medications to squash potential competitors, including through unlawful exclusivity agreements with telehealth providers, a compounding pharmacy alleged Wednesday in what it calls a landmark antitrust lawsuit.